Santiago Viteri

6PUBLICATIONS
48CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 16, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|Nov 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Xiuning Le, Hiroshi Sakai, Enriqueta Felip

|Aug 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.

Marta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal

|Jul 29, 2021
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Raquel Laza-Briviesca, Alberto Cruz-Bermúdez, Ernest Nadal

|Dec 30, 2020
RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients.

Cristina Aguado, Ana Giménez-Capitán, Ruth Román

|Oct 18, 2018
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Florence Atrafi, Harry J M Groen, Lauren A Byers

Pageof 1

Frequent Collaborators

3 joint publications

Atocha Romero

3 joint publications

Alberto Cruz-Bermúdez

3 joint publications

Ernest Nadal

3 joint publications

Amelia Insa